Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.

Many VAX004 participants also had declining anti-V3 Ab responses, but the decrease did not reach statistical significance.

also in 111,027 other papers

Post hoc analysis of VAX004 further showed a trend toward lower HIV incidence among vaccinees with CD4-blocking and V2- and V3-binding Ab activity versus placebo recipients, and higher levels of these Abs were seen in nonwhite and female volunteers 4 .

also in 53,322 other papers